Pharmaceutical Exporter from India to Kenya.
Kenya is the regulatory, logistics and commercial pivot of East Africa, and M Care's East-African anchor. We supply PPB-registered product into Kenyatta National Hospital, Moi Teaching & Referral in Eldoret, Aga Khan University Hospital Nairobi and the Nairobi Hospital, with regional trans-shipment running from Jomo Kenyatta International into Uganda, Rwanda, Burundi and eastern DRC. Orders reach us from procurement offices in Nairobi, Mombasa, Kisumu, Nakuru and Eldoret; the commercial, regulatory and dispatch work is run from our Mumbai office.
PPB, KEMSA and the Kenyan approvals sequence.
The Pharmacy and Poisons Board (PPB) is the regulator for human medicines in Kenya. Every finished pharmaceutical imported into Kenya must be registered on the PPB register, linked to a Kenyan local technical representative, and moved in against an import permit issued through the PvERS portal. Dossiers follow the ACTD/CTD structure with Module 1 Kenya-specific administrative content, Module 2 overall summaries, Module 3 quality with stability under ICH Zone IVb (30°C/75%RH for twelve months), and a CoPP authenticated via the Indian Ministry of External Affairs and the Kenyan High Commission.
The East African Community joint scientific review has been operational for priority molecules since 2018, and for eligible products a single regional dossier can secure parallel national approvals across Kenya, Uganda, Tanzania, Rwanda and Burundi, compressing time-to-market by several months. For everything outside the priority list we file nationally at PPB and mirror the submission at NDA Uganda, TMDA Tanzania and Rwanda FDA where the same molecule is needed for the regional programme.
Public-sector procurement is anchored by the Kenya Medical Supplies Authority (KEMSA), which runs the national essential-medicines tender cycle and supplies the 47 county governments. The Social Health Authority (SHA), operational since October 2024, replaced NHIF as the payer framework and is rebuilding the benefit-package formulary; managed-entry agreements are emerging for oncology and chronic-disease lines. Retail and wholesale pharmacy practice is licensed by PPB through the Part I, Part II and Part III categories; controlled substances require parallel endorsement from the PPB narcotics desk.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · [email protected] · Mon–Sat 09:30–18:30 IST
Five capabilities the Nairobi desk runs on.
PPB registration and PvERS filing
In-house regulatory team files full CTD dossiers on PvERS, manages sample submission and lab re-analysis, and lodges variations and renewals against the PPB five-year cycle.
KEMSA and county tender response
Technical bid packages for KEMSA national tenders, county framework agreements and SHA-linked facility procurement. We bid through PPB-licensed Kenyan distributors with the tender-board track record.
Private hospital formulary supply
Direct lines into Aga Khan University Hospital Nairobi, Nairobi Hospital, MP Shah, Mater Misericordiae, Avenue Hospital and Karen Hospital formulary committees via Surgipharm, Phillips Pharmaceuticals and Laboratory & Allied.
East Africa trans-shipment
Bonded and duty-paid warehousing at JKIA and Mombasa for onward consolidation into Kampala, Kigali, Bujumbura, Dar es Salaam and Goma, with EAC certificate-of-origin support.
EAC joint-review dossiers
For eligible priority molecules, we prepare a single joint-review dossier that yields parallel Kenyan, Ugandan, Tanzanian and Rwandan approvals, reducing combined time-to-market by nine to twelve months.
From Mumbai to JKIA, Mombasa and the East African hinterland.
Air consignments consolidate at Mumbai (BOM), with Kenya Airways Cargo, Emirates SkyCargo, Qatar Airways Cargo and Ethiopian Airlines the routine carriers into Jomo Kenyatta International (NBO). Door-to-door air cycle from our Bhiwandi warehouse to a Nairobi 3PL runs three to five calendar days on direct services. Sea consignments route via Nhava Sheva or Mundra to the Port of Mombasa (KPA) on a 16 to 22-day transit, with the Mombasa–Nairobi Standard Gauge Railway cargo service giving 8-hour inland relay into the Embakasi Inland Container Depot. Pharmaceutical cold-chain almost always routes air into NBO rather than sea into Mombasa.
Cold-chain packaging for Kenyan shipments leans on validated passive shippers, Sonoco ThermoSafe Certis and va-Q-tec TW70 for 96-hour 2–8°C excursions, va-Q-tec TWIV1000C for -20°C oncology consignments, and Envirotainer RKN e1 active containers for tranches above 400 kg. Every cold-chain pallet carries Berlinger Q-tag 2 plus ELPRO LIBERO GE dual loggers. Our Nairobi 3PL holds 2–8°C and -20°C buffer, with onward splits to Mombasa by road (eight hours), Kisumu (six hours), Eldoret (five hours) and trans-shipment by road/air to Kampala (twelve hours), Kigali (twenty-four hours) and Dar es Salaam (fourteen hours by truck).
Payment structure for Kenyan buyers is usually cleaner than the West African norm. Private hospital chains settle on 30 to 60-day open account once vendor accreditation clears, with hedging against KES–USD movement at the distributor level. KEMSA and county tenders settle on contract-award schedule, sometimes with a performance bond held by a Kenyan commercial bank. For new importers we start on an irrevocable LC confirmed by an acceptable bank, then graduate to CAD or open account with ATI credit-insurance cover. USD is the trading currency; KES pricing is built in at the distributor.
The therapeutic portfolio matched to Kenya's disease burden.
Kenya's disease profile is a shifting mix. HIV remains significant but much of the ARV volume sits inside donor-funded Global Fund and PEPFAR pipelines that move through closed procurement channels; M Care supplies the SHA, private and county-level gap rather than competing with donor supply. Our Kenyan ARV volumes are weighted toward second-line and salvage regimens, paediatric formulations and opportunistic-infection therapies. Anti-TB fixed-dose combinations on the NTLD programme formulary and second-line MDR-TB regimens are a stable line.
Malaria burden is lower than in West Africa but still material in coastal and western Kenya; we ship artemether-lumefantrine, injectable artesunate and rapid diagnostic test kits into the malaria-endemic counties. The fastest-growing categories are non-communicable disease, metformin, gliclazide, empagliflozin, amlodipine, losartan, atorvastatin, insulin analogues, which now dominate private-retail volume and are central to SHA's chronic-disease basket. Oncology supply into Aga Khan University Hospital, Kenyatta National and Nairobi Hospital covers cytotoxics, supportive care and a growing biosimilars line. Maternal-child health lines, oxytocin, magnesium sulphate, paediatric amoxicillin dispersible tablets, zinc-ORS sachets, complete the essential spine.
A Nairobi private hospital group with four facilities consolidated its oncology and critical-care sourcing under M Care through a single Kenyan distributor in early 2025. We transferred 62 PPB registrations to the new commercial partner inside fourteen weeks, stood up a -20°C buffer for cytotoxics at the Nairobi 3PL, and closed the first two quarters at 99.1% on-time-in-full across 187 SKUs with zero temperature excursions logged on shipment. The group's pharmacy & therapeutics committee added three M Care biosimilars to the 2025 formulary on the back of the transition.
Working with an Indian supplier from Kenya.
Kenyan procurement tends to be more regulatory-literate than most African buyers, with a high proportion of pharmacists and biomedical scientists on the purchasing side. That raises the bar on what is acceptable in a technical bid, and it is why Kenyan buyers often tell us that half the Indian proposals they receive fail on document quality rather than pricing. M Care's value is in the regulatory hygiene: a PPB-ready dossier, a CoPP that has actually been authenticated, a stability summary that matches the WHO Zone IVb requirement and artwork that already carries the PPB registration number in the correct placement.
The practical engagement sequence runs like this. Week one, the Mumbai desk takes the molecule list, the destination facility or tender reference, pack sizes and commercial terms, and returns a manufacturer short-list with PPB registration status for each SKU, a landed price in USD and CIF Nairobi or DDP options. Weeks two to six, we either transfer an existing PPB registration to your preferred Kenyan distributor or lodge a fresh CTD dossier on PvERS, alongside sample submission for lab re-analysis. Weeks six to twelve cover the registration review and deficiency cycle. First dispatch follows immediately on approval, usually by air into NBO for hospital formulary work.
You work with one named account manager in Mumbai, a regulatory technical contact, and a logistics contact handling the Nairobi 3PL interface. There is no local phone number, M Care runs a Mumbai desk, a London commercial presence and a Dubai GCC office, and every Kenyan enquiry moves through the same WhatsApp channel rather than a disconnected Nairobi branch. Standard quote turnaround is one working day; regulatory feasibility including PPB registrability, BE waiver prospects and labelling feasibility is three to five working days.
PPB and PvERS: registration mechanics, lab analysis and inspection schedule.
The Pharmacy and Poisons Board (PPB) operates across four working directorates that any importer should know by name. The Product Evaluation and Registration directorate owns dossier review and registration certificate issuance; submissions move through the PvERS (Pharmacovigilance and Electronic Regulatory Information System) portal which closed the paper route for new applications during the 2021-2022 transition, with module uploads in ACTD or eCTD format and fee payment receipted against the application number. The Inspectorate and Enforcement directorate runs site inspections of overseas manufacturers and the licensing of Kenyan importers, wholesalers, and retail pharmacies under Part I, Part II and Part III categories. The Pharmacovigilance directorate operates Pharmacovigilance Yellow Card reporting integrated into PvERS and consolidates national ADR signals for the WHO PIDM database. The National Quality Control Laboratory (NQCL), co-located with PPB, runs the mandatory lab re-analysis of registration samples and post-market surveillance batches.
Three operational gates set the actual timeline. First, the fee and sample gate: PPB registration fees are published in Kenyan Shillings and revised periodically (we share current amounts at quote stage); three validated batches of samples plus reference standards are submitted to NQCL alongside the dossier for chemical and microbiological re-analysis, with NQCL turnaround typically four to ten weeks on standard generics and longer on biologicals. Second, the inspection gate: PPB accepts WHO-Prequalification and recent PIC/S, EU-GMP or US FDA inspection reports under its collaborative regulatory reliance framework for routine-list molecules, while first-time registration of any biological, vaccine, antimalarial, antitubercular or oncology product triggers the Overseas Site Inspection Programme (importer or applicant bears inspection cost, typically four to six months scheduling lead). Third, the variation gate: post-approval CMC changes follow the ICH-aligned Type IA, IB and II framework, filed through the same PvERS portal as the original registration. The PPB renewal cycle runs five years; the in-house regulatory desk holds the PvERS baseline so renewals and variations are a one-pass upload rather than a rebuild.
Kenyan buyer questions, answered straight.
How long does Pharmacy and Poisons Board (PPB) registration take in Kenya?
A complete CTD dossier lodged through the PPB online Pharmacovigilance and Electronic Regulatory Information System (PvERS) generally moves in ten to fourteen months for generic finished products. Samples and three validated batches for analysis are submitted alongside the dossier. We front-load the CoPP, site master file, stability under ICH Zone IVb and bioequivalence to compress the deficiency-response cycle.
Can dossiers be filed through the EAC joint regional procedure?
The East African Community joint scientific review is operational for priority products, with Kenya, Tanzania, Uganda, Rwanda and Burundi as participating states. For eligible molecules a single dossier can yield parallel national approvals. For everything outside the priority list, we file nationally at PPB and mirror the submission at NDA Uganda, TMDA Tanzania and Rwanda FDA to compress regional roll-out.
How do we bid into KEMSA public-sector tenders?
Only Kenya-registered entities can bid into KEMSA tenders. We partner with a PPB-licensed Kenyan distributor who files the bid on behalf of the manufacturer; M Care provides the full technical bid package, registration certificates, CoA, stability summary, manufacturing licence and the pro-forma. SHA-linked county procurement works similarly, through county-level framework agreements.
Which Kenyan airport and port do M Care shipments route through?
Jomo Kenyatta International (NBO) is our primary pharmaceutical hub; cold-chain and high-value consignments move air into NBO with Kenya Airways Cargo, Emirates SkyCargo and Qatar Airways Cargo as the preferred carriers. Sea freight moves through Mombasa (KPA), with bonded warehousing available for regional trans-shipment into Uganda, Rwanda, Burundi, eastern DRC and northern Tanzania.
Does M Care supply Aga Khan, Nairobi Hospital and the private hospital tier?
Yes. We ship into the Aga Khan University Hospital Nairobi formulary through their approved distributor, into Nairobi Hospital, Mater Misericordiae, MP Shah and Avenue Hospital via Surgipharm, Phillips Pharmaceuticals and Laboratory & Allied, and directly into county referral hospitals through their framework-agreement suppliers. Private-sector contracts run on CIF Nairobi or DDP terms depending on the chain.
How is the SHA transition from NHIF affecting pharmaceutical procurement?
The Social Health Authority (SHA) replaced NHIF from October 2024 and is rebuilding the benefit-package formulary, with an expanded chronic-disease basket and managed-entry agreements for oncology. Procurement pathways are in transition; we track the SHA Benefits Package Advisory Panel outputs and adapt our county-level and private-tier supply accordingly. Private-pay and insurance business runs undisturbed.
How does M Care handle the USAID/PEPFAR displacement risk in Kenya's HIV supply chain?
PEPFAR/Global Fund ARV programmes move through Chemonics and parallel donor channels that are closed to us. We do not compete with donor supply. Our Kenyan ARV volumes sit in the SHA-funded, private-sector and county-level gap, second-line regimens, paediatric formulations and opportunistic-infection therapies where donor coverage is partial. If donor funding contracts, that gap widens and M Care has the WHO-prequalified alternatives queued.
How does the PPB PvERS portal change the dossier-submission workflow?
PPB's PvERS (Pharmacovigilance and Electronic Regulatory Information System) portal is the mandatory submission channel since the 2021-2022 paper-route closure. The portal handles the full cycle: importer registration, product application, fee payment against the application number, ACTD or eCTD dossier upload (Module 1 Kenya-specific including the local technical representative appointment and PPB-compliant artwork, Modules 2-5 technical), sample submission tracking to the National Quality Control Laboratory (NQCL), reviewer assignment and deficiency-letter response, and registration certificate issuance plus the five-year renewal scheduling. We prepare the ACTD/eCTD baseline locally in Mumbai so the importer's portal upload is a one-pass file transfer; for variations and renewals the same baseline is reused, which compresses each cycle by weeks compared with a build-as-you-go upload.
Does PPB inspect Indian manufacturers before granting registration?
Yes for new sites, conditionally for established sites. PPB operates an Overseas Site Inspection Programme under which inspectors travel to Indian (or other origin-country) plants for first-time registration of high-risk molecules, biologicals, vaccines, antimalarials, antituberculars and oncology products. For molecules on the routine list at WHO-Prequalified sites or sites with a recent PIC/S, EU-GMP or US FDA inspection on the same product line, PPB will accept the foreign inspection report in lieu of an own visit under its collaborative regulatory reliance framework. Inspection costs are borne by the importer or applicant. We coordinate the scheduling between PPB headquarters and the Indian partner plant; typical lead time is four to six months from approval to inspection.
What is the NQCL lab re-analysis requirement and timeline?
The National Quality Control Laboratory (NQCL), co-located with PPB, runs the mandatory pre-registration lab re-analysis of every imported pharmaceutical. Three validated batches of registration samples are submitted alongside reference standards and the analytical method file. NQCL runs the full quality-control battery: HPLC assay against the agreed monograph, related substances per Ph.Eur./USP/BP, dissolution profile, content uniformity, microbiological purity, packaging integrity. Standard generic finished-dose turnaround is four to ten weeks; biologicals and complex molecules run longer. NQCL deficiencies trigger a sample re-submission, so the pre-shipment QC on the manufacturer side has to be tight. NQCL also runs the post-market surveillance batches that the inspectorate pulls from importers' warehouses, so the supply-side QC discipline carries through after registration.
What are the current PPB registration fees by product category?
PPB publishes its registration fee schedule in Kenyan Shillings and revises it periodically through Kenya Gazette notices. The schedule has separate tiers for new chemical entity registration, generic finished-dose registration, line-extension and variation, vaccine and biological registration (with additional lot-release charges per batch), and renewal at the five-year cycle. We share the current Naira-equivalent USD amounts at quote stage rather than freezing a stale number in HTML. Fees are paid through the PvERS portal against the application number, and the receipt is uploaded back into the application package; the receipt number is also referenced on the inspection-fee submission for overseas-site inspections.
How long does a PPB post-approval variation (CMC change) take?
PPB categorises variations under the ICH-aligned framework: Type IA (notification-only, take effect immediately, file the notification within 12 months), Type IB (60 days for PPB review, 'tell, wait, do' if PPB raises no objection), and Type II (major change, six to nine months including a formal review and possibly an updated overseas-site inspection). Typical examples: pack-size change (Type IA), excipient supplier change with no specification impact (IB), specification change or manufacturing-site transfer (II). We file variations through the importer's PvERS portal access using the same ACTD/eCTD baseline format as the original registration, so the variation dossier reuses the source pack without retrofit cost. The five-year registration renewal sits separately from variations and runs through PvERS as a structured cycle that we time-bound 12 months ahead of expiry.
Why buyers choose M Care for the India → Kenya corridor.
PPB fluency
Dossiers built to the exact format PPB reviews, not a generic CTD dump. We know which modules get scrutinised first, which stability data triggers queries, and which legalisation and apostille chain the submission needs to clear on the first pass.
Logistics you can schedule around
BOM → NBO direct air for time-critical orders, and Mombasa for high-volume ambient sea freight. Cold-chain SKUs run on validated containers with continuous temperature logging. Consolidation at origin so you order by molecule, not by MOQ.
Commercial discipline, one point of contact
USD invoicing with clear FX-clause language, LC / TT / open-account progression as the relationship proves out, 18 therapeutic areas on one PO, and one named account manager from enquiry through clearance in Kenya.
Top categories we ship to Kenya
Anti-infectives
Penicillins, cephalosporins, carbapenems including meropenem for KEMSA carbapenem basket and Kenyatta National Hospital ICU formulary, antivirals, antimalarials, 1,800+ hospital and retail lines.
Cardiovascular
Antihypertensives, statins, anticoagulants, antiarrhythmics and heart-failure lines.
Oncology
Cytotoxics, targeted therapy and supportive care: bortezomib on KEMSA tender and Kenyatta National Hospital myeloma protocols and imatinib for KEMSA and KNH Cancer Treatment Centre CML supply, plus docetaxel, paclitaxel and gemcitabine.
Diabetes & endocrine
Insulins including insulin glargine for KEMSA diabetes basket and KNH endocrinology clinic, oral antidiabetics, thyroid and hormonal therapy, 470+ lines across the spectrum.
CNS & neurology
Antiepileptics, antipsychotics, antidepressants, anxiolytics and neuroprotective lines.
General & OTC
Analgesics, vitamins, wound-care, nutritionals, 1,283 SKUs, our broadest catalogue.
Services that fit Kenya procurement workflows.
Government supply services
KEMSA national tender bidding, county framework agreements, SHA-linked facility procurement via PPB-licensed Kenyan distributors.
NGO and donor-funded procurement
Global Fund Kenya principal-recipient supply, CHAI catalogue, MSF and AMREF channels, KEMSA NGO basket.
CTD dossier preparation
PPB eCTD via PvERS, BE-study site selection, EAC joint-review dossiers covering Kenya plus Uganda, Tanzania and Rwanda in one filing.
WHO-GMP compliance
Manufacturer CoPP, Site Master File and CDSCO inspection package for Kenyatta National Hospital tender prequalification.
Cold-chain validation
JKIA inbound on Kenya Airways Cargo, qualified shipper temperature logs, Nairobi customs cold-store handover.
Molecule, volume, destination facility. One working day to a quote.
Your enquiry lands with the Mumbai account manager responsible for Kenya. No call-centre hops, no disconnected Nairobi branch, no generic autoresponders. WhatsApp is the fastest route in.
Start a Kenya enquiry → Back to all markets